ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX

Shares of Novavax Inc. plunged more than 83% in extended trading on Thursday, following the failure of its phase III trial of respiratory syncytial virus fusion (F) protein nanoparticle vaccine candidate.

from RTT - Biotech http://ift.tt/2cKctXf
via IFTTT